Adamax vs Humanin
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Half-Life
- Estimated 1-3 hours (short; peptide degradation)
- ~4–8 hours (HNG)
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 200-400 mcg per dose
- 2–8 mg
- Frequency
- Once daily or every other day
- 3–5 times per week
- Key Benefits
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Side Effects
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Injection site irritation
- Limited human safety data available
- Stacks With
- —
- —